NEW YORK ( TheStreet) -- InterMune (Nasdaq: ITMN) is trading at unusually high volume Tuesday with four million shares changing hands. It is currently at 4.1 times its average daily volume and trading down $2.67 (-9.9%) at $24.20 as of four p.m. ET. InterMune has a market cap of $1.6 billion and is part of the health care sector and drugs industry. Shares are down 26.2% year to date as of the close of trading on Monday. InterMune, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies in pulmonology and hepatology. The company primarily offers Actimmune for the treatment of chronic granulomatous disease and severe malignant osteopetrosis. The company has a P/E ratio of 12.3, below the average drugs industry P/E ratio of 13.1 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates InterMune as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full InterMune Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.